Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. (Q50457532)

14 March 2018

title

Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. (English)

1 reference

14 March 2018

0 references

1 reference

2

Mario Sznol

1 reference

14 March 2018

Madhav V Dhodapkar

1

1 reference

14 March 2018

Biwei Zhao

3

1 reference

14 March 2018

Ding Wang

4

1 reference

14 March 2018

Richard D Carvajal

5

1 reference

14 March 2018

Mary L Keohan

6

1 reference

14 March 2018

Ellen Chuang

7

1 reference

14 March 2018

Rachel E Sanborn

8

1 reference

14 March 2018

Jose Lutzky

9

1 reference

14 March 2018

John Powderly

10

1 reference

14 March 2018

Harriet Kluger

11

1 reference

14 March 2018

Sheela Tejwani

12

1 reference

14 March 2018

Jennifer Green

13

1 reference

14 March 2018

Venky Ramakrishna

14

1 reference

14 March 2018

Andrea Crocker

15

1 reference

14 March 2018

Laura Vitale

16

1 reference

14 March 2018

Michael Yellin

17

1 reference

14 March 2018

Thomas Davis

18

1 reference

14 March 2018

Tibor Keler

19

1 reference

14 March 2018

language of work or name

English

0 references

publication date

1 April 2014

1 reference

14 March 2018

Science Translational Medicine

published in

1 reference

14 March 2018

volume

6

1 reference

14 March 2018

issue

232

1 reference

14 March 2018

page(s)

232ra51

1 reference

14 March 2018

The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing

cites work

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008068

A monoclonal antibody to the DEC-205 endocytosis receptor on human dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008068

DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8+ T cells in a spectrum of human MHC I haplotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008068

Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008068

Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008068

The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008068

In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008068

Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008068

Human dendritic cell subsets from spleen and blood are similar in phenotype and function but modified by donor health status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008068

Roles of toll-like receptors in natural interferon-producing cells as sensors in immune surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008068

Toll-like receptor signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008068

Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008068

Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008068

Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008068

A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008068

Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008068

Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008068

NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008068

Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008068

Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008068

Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008068

Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008068

Phase I clinical trial of mixed bacterial vaccine (Coley's toxins) in patients with NY-ESO-1 expressing cancers: immunological effects and clinical activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008068

Efficient in vivo priming by vaccination with recombinant NY-ESO-1 protein and CpG in antigen naive prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008068

Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008068

Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008068

Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008068

Improved cellular and humoral immune responses in vivo following targeting of HIV Gag to dendritic cells within human anti–human DEC205 monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008068

Toll-like receptor activation enhances cell-mediated immunity induced by an antibody vaccine targeting human dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008068

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008068

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008068

CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008068

Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008068

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008068

Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008068

A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008068

A cancer vaccine induces expansion of NY-ESO-1-specific regulatory T cells in patients with advanced melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008068

SOX2-specific adaptive immunity and response to immunotherapy in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008068

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008068

Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008068

Dendritic cells in vivo: a key target for a new vaccine science

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24739759

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24739759

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1126/SCITRANSLMED.3008068

1 reference

14 March 2018

PMC publication ID

6151129

0 references

1 reference

14 March 2018